Involvement of L-carnitine in cellular metabolism: Beyond Acyl-CoA transport

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 13, 2009, Pages 1518-1526

  Chapela, S P ^a   Kriguer, N ^a   Fernandez E H ^a   Stella, C A ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Acetyl L carnitine; Acetylation; Apoptosis; Carnitine; Free radicals

Indexed keywords

ACYL COENZYME A; CARNITINE; FREE RADICAL; LEVACECARNINE; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PLACEBO;

ACETYLATION; ALZHEIMER DISEASE; APOPTOSIS; CELL METABOLISM; CLINICAL TRIAL; DRUG ABSORPTION; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FISH; HUMAN; IN VITRO STUDY; MEAT; MITOCHONDRIAL MEMBRANE; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; SHORT SURVEY;

ACETYLATION; ACYL COENZYME A; ANIMALS; APOPTOSIS; BIOLOGICAL TRANSPORT; CARNITINE; HUMANS; ORGANIC CATION TRANSPORT PROTEINS;

EID: 75449115742     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709790361502     Document Type: Short Survey

References (68)

1. Stella C.A.; Burgos H.I.; Salellas M.; Cristaldo M.L.; Ramos E.H. and Kriguer N. L-Carnitine Effect upon Iron Growth Inhibition on Saccharomyces cerevisiae. Lett. Drug Dis. Dev., 2005, 2, 184-193.
2. Ganapathy, M. E.; Huang, W.; Raja. D. P.; Carter, A. L.; Sugawara, M.; Iseki, K.; Leibach, F. H.; Ganapathy, V. Betalactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem., 2000, 275, 1699-707.
3. Tamai, I.; Ohashi, R.; Nezu, J.; Sai, Y.; Kobayashi, D.; Oku, A.; Shimane, M.; Tsuji, A. Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem., 2000, 275, 40064-72
4. Inano, A.; Sai, Y.; Kato, Y.; Tamai, I.; Ishiguro, M.; Tsuji, A. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition. Drug Metab. Phamacokinet., 2004, 19, 180-9.
5. Tamai, I.; Ohashi, R.; Nezu, J.; Yabuuchi, H.; Oku, A.; Shimane, M.; Sai, Y.; Tsuji, A. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem., 1998, 273, 20378-82.
6. Grube, M.; Schwabedissen, H. E. U. M.; Präger D.; Haney, J.; Möritz, K.; Meissner, K.; Eckel, L.; Böhm, M.; Jedlitschky, G.; Kroemer, H. K. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation, 2006, 113, 1114-22.
7. Maeda, T.; Wakasawa, T.; Funabashi, M.; Fukushi, A.; Fujita, M.; Motojima, K.; Tamai, I. Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha. Biol. Pharm. Bull., 2008, 31, 1230-6.
8. Wagner, C. A.; Lükewille, U.; Kaltenbach, S.; Moschen, I.; Bröer, A.; Risler, T.; Bröer, S.; Lang, F. Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2. Am. J. Physiol. Renal Physiol., 2000, 279, 584-91.
9. Wu, X.; Huang, W.; Prasad, P. D.; Seth, P.; Rajan, D. P.; Leibach F. H.; Chen, J.; Conway, S. J.; Ganapathy, V. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J. Pharmacol. Exp. Ther, 1999, 290, 1482-92.
10. Ohashi, R.; Tamai, I.; Yabuuchi, H.; Nezu, J.; Oku, A.; Sai, Y.; Shimane, M.; Tsuji, A. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J. Pharmacol. Exp. Ther., 1999, 291, 778-84.
11. Ohashi, R.; Tamai, I.; Nezu, J.; Nikaido, H.; Hashimoto, N.; Oku, A.; Sai, Y.; Shimane, M.; Tsuji, A. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol. Pharmacol., 2001, 59, 358-66.
12. Kato, Y.; Sugiura, M.; Sugiura, T.; Wakayama, T.; Kubo, Y.; Kobayashi, D.; Sai, Y.; Tamai, I.; Iseji, S.; Tsuji, A. Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. Mol. Pharmacol., 2006, 70, 829-37.
13. Iwata, D.; Kato, Y.; Wakayama, T.; Sai, Y.; Kubo, Y.; Iseji, S.; Tsuji, A. Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. Drug Metab. Pharmacokinet., 2008, 23, 207-15.
14. Berezowski, V.; Miecz, D.; Marszalek, M.; Bröer, A.; Bröer, S.; Cecchelli, R.; Nalecz, K. A. Involvement of OCTN2 and B0,+ in the transport of carnitine through an in vitro model of the bloodbrain barrier. J. Neurochem., 2004, 91, 860-72.
15. Nalecz, K. A.; Miecz, D.; Berezowski, V.; Ceccheli, R. Carnitine: transport and physiological functions in the brain. Mol. Aspects Med., 2004, 25, 551-67.
16. Inano, A.; Sai, Y.; Nakaido, H.; Hashimoto, N.; Asamo, M.; Tsuji, A.; Tamai, I. Acetyl-L-carnitine permeability across the bloodbrain barrier and involvement of carnitine transporter OCTN2. Biopharm. Drug Dispos., 2003, 24, 357-65.
17. Miecz, D.; Januszewicz, E.; Czeredys, M; Hinton, B.T.; Berezowski, V.; Cecchelli, R.; Nalecz, K. A. Localization of organic cation/carnitine transporter (OCTN2) in cells forming the bloodbrain barrier. J. Neurochem., 2008, 104, 113-23.
18. Vaz, F. M.; Wanders, R. J. A. Carnitine biosynthesis in mammals. Biochem. J., 2002, 361, 417-29.
19. Rebouche, C. J. Carnitine function and requirements during the life cycle. FASEB J., 1992, 6, 3379-86.
20. Evans, A.M.; Fornasini, G. Pharmacokinetics of L-carnitine. Clin. Pharmacokinet., 2003, 42, 941-67.
21. Rebouche, C.J.; Chenard, C. A. Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. J. Nutr., 1991, 121, 539-46.
22. Rebouche, C.J. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann. N. Y. Acad. Sci., 2004, 1033, 30-41.
23. Farrel, S.; Vogel, J.; Bieber, LL. Entry of acetyl-L-carnitine into biosynthetic pathways. Biochim. Biophys. Acta, 1986, 876, 175-7.
24. Pettegrew, J. W.; Levine.; McClure, R. J. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol. Psychiatry, 2000, 5, 616-32.
25. Kiernan, R.; Brès, V.; NG, R. W. M.; Coudart, M.; El Messaoudi, S.; Sardet, C.; Jin, D.; Emiliani, S.; Benkirane, M. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem., 2003, 278, 2758-66.
26. Chiechio, S.; Copani, A.; De Petris, L.; Morales, M. E. P.; Nicoletti, F.; Gereau IV, R. W. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-kappaB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine. Mol. Pain, 2006, 2, 20.
27. Pomponi, M. G.; Neri, G. Butyrate and acetyl-carnitine inhibit the cytogenetic expression of the fragile X in vitro. Am. J. Med. Genet., 1994, 51, 447-50.
28. Higa, H. H.; Butor, C.; Diaz, S.; Varki, A. O-acetylation and de-O-acetylation of sialic acids. O-acetylation of sialic acids in the rat liver Golgi apparatus involves an acetyl intermediate and essential histidine and lysine residues -a transmembrane reaction? J. Biol. Chem., 1989, 264, 19427-34.
29. Mazzarelli, P.; Pucci, S.; Bonano, E.; Sesti, F.; Calvani, M.; Spagnoli, L. G. Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation? Cancer Biol. Ther., 2007, 6, 1606-13.
30. Friedlander, R. M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med., 2003, 348, 1365-75.
31. Qi, S.; Zhang, Z.; Wang, Z.; Yoshida, A.; Ueda, T. L-carnitine inhibits apoptotic DNA fragmentation induced by a new spinlabeled derivative of podophyllotoxin via caspase-3 in Raji cells. Oncol. Rep., 2006, 15, 119-22.
32. Vescovo, G.; Ravara, B.; Gobbo, V.; Sandri.; Angelini, A.; Della Barbera, M.; Dona, M.; Peluso, G.; Calvani, M.; Moscón, L.; Dalla Libera, L. L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am. J. Physiol. Cell Physiol., 2002, 283, 802-10.
33. Tamilselvan, J.; Jayaraman, G.; Sivarajan, K.; Panneerselvan, C. Age-dependent upregulation of p53 and cytochrome c release and susceptibility to apoptosis in skeletal muscle fiber of aged rats: role of carnitine and lipoic acid. Free Radic. Biol. Med., 2007, 43, 1656-69.
34. Ishii, T.; Shimpo, Y.; Matsuoka, Y.; Kinoshita, K. Anti-apoptotic effect of acetyl-l-carnitine and I-carnitine in primary cultured neurons. J. Pharmacol., 2000, 83, 119-24.
35. Di Cesare Mannelli, L.; Ghelardini, C.; Calvani, M.; Nicolai, R.; Mosconi, L.; Vivoli, E.; Pacini, A.; Bartolini, A. Protective effect of acetyl-L-carnitine on the apoptotic pathway of peripheral neuropathy. Eur. J. Neurosci., 2007, 26, 820-7.
36. Abdul, H. M.; Calabrese, V.; Calvani, M.; Butterfield, D. A. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res., 2006, 84, 398-408.
37. Abdul, H. M.; Butterfield, D. A. Involvement of PI3K/PKG-/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. Free Radic. Biol. Med., 2008, 42, 371-84.
38. Dhitavat, S.; Ortiz, D.; Shea, T. B.; Rivera, E. R. Acetyl-Lcarnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochem. Res., 2002, 27, 501-5.
39. Liu, J.; Head, E.; Kuratsune, H.; Cotman, C. W.; Ames, B. N. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann. N. Y. Acad. Sci., 2004, 1033, 117-31.
40. Al-Majed, A. A.; Sayed-Ahmed M. M.; Al-Omar F. A.; Al-Yahya A. A.; Aleisa A. M.; Al-Shabanah, O. A. Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus. Clin. Exp. Pharmacol. Physiol., 2006, 33, 725-33.
41. Sener, G.; Ekşioǧlu-Demiralp, E.; Cetiner, M.; Ercan, F.; Sirvanci, S.; Gedik, N.; Yeǧen, B. C. L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol. Toxicol., 2006, 22, 47-60.
42. Strauss, M.; Porras, N. Differential expression of HSP70 and ultrastructure of heart and liver tissues of rats treated with adriamycin: protective role of L-carnitine. Invest. Clin., 2007, 48, 33-43.
43. Yapar, K.; Kart, A.; Karapehlivan, M.; Atakisi, O.; Tunca, R.; Erginsoy, S.; Citil, M. Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice. Exp. Toxicol. Pathol., 2007, 59, 121-8.
44. Mansour H. H. Protective role of carnitine ester against radiation-induced oxidative stress in rats. Pharmacol. Res., 2006, 54, 165-71.
45. Kocer, I.; Taysi, S.; Ertekin, M. V.; Karslioglu, I.; Gepdiremen, A.; Sezen, O.; Serifoglu, K. The effect of L-carnitine in the prevention of ionizing radiation-induced cataracts: a rat model. Graefes Arch. Clin. Exp. Ophthalmol., 2007, 245, 588-94.
46. Garcia, C. L.; Filippi, S.; Mosesso, P.; Calvani, M.; Nicolai, R.; Palitti, F. The protective effect of L-carnitine in peripheral blood human lymphocytes exposed to oxidative agents. Mutagenesis, 2006, 21, 21-7.
47. Calabrese, V.; Giuffrida Stella, A. M.; Calvani, M.; Butterfield, D.A. Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J. Nutr. Biochem., 2006, 17, 73-88.
48. Derin, N.; Izgut-Uysal, V. N.; Agac, A.; Aliciguzel, Y.; Demir, N. L-carnitine protects gastric mucosa by decreasing ischemia-reperfusion induced lipid peroxidation. J. Physiol. Pharmacol., 2004, 55, 595-606.
49. Dokmeci, D., Akpolat, M.; Aydogdu, N.; Doganay, L.; Turan, F. N. L-carnitine inhibits ethanol-induced gastric mucosal injury in rats. Pharmacol. Rep., 2005, 57, 481-8.
50. Chiechio, S.; Copani, A.; Gereau, R.W. 4th; Nicoletti, F. Acetyl-L-carnitine in neuropathic pain: experimental data. C.N.S. Drugs, 2007, 21, 31-8.
51. Malone, J. I.; Lowitt, S.; Salem, A. F.; Miranda, C.; Korthals, J. K.; Carver, J. The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes. Metabolism, 1996, 45, 902-7.
52. Hart, A. M.; Wiberg, M.; Youle, M.; Terenghi G. Systemic acetyl-L-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma. Exp. Brain Res., 2002, 145, 182-9.
53. Chiechio, S.; Caricasole, A.; Barleta, E.; Storto, M.; Catania, M. V.; Copani, A.; Vertechy, M.; Nicolai, R.; Calvani, M.; Melchiorri, D.; Nicoletti, F. L-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol. Pharmacol., 2002, 61, 989-96.
54. Ghelardini, C.; Galeotti, N.; Calvani, M.; Mosconi, L.; Nicolai, R.; Bartolni, A. Acetyl-l-carnitine induces muscarinic antinocieption in mice and rats. Neuropharmacology, 2002, 43, 1180-7.
55. Chiechio, S.; Copani, A.; Nicoletti, F. Gereau, R.W. IV. Lacetylcarnitine: a proposed therapeutic agent for painful peripheral neuropathies. Curr. Neuropharmacol., 2006, 4, 233-7.
56. De Grandis, D.; Minardi, C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs RD, 2002, 3, 223-31.
57. Sima, A. A. F.; Calvani, M.; Mehra, M.; Amato, A. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care, 2005, 28, 89-94.
58. Montgomery, S. A.; Thal, L. H.; Amrein, R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int. Clin. Psychopharmacol., 2003, 18, 61-71.
59. Thal, L. J.; Calvani, M.; Amato, A.; Carta, A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology, 2000, 55, 805-10.
60. Brooks III, J. O.; Yesavage, J. A.; Carta, A.; Bravi, D. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int. Psychogeriatr., 1998, 10, 193-203.
61. Thal, L. J.; Carta, A.; Clarke, W. R.; Ferris, S. H.; Friedland, R. P.; Petersen, R. C.; Pfeiffer, E.; Raskind, M. A.; Sano, M.; Tuszynki, M. H.; Woolson, R. F. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology, 1996, 47, 705-11.
62. Bianchetti, A.; Rozzini, R.; Trabucchi, M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr. Med. Res. Opin., 2003, 19, 350-3.
63. Mayeux, R.; Sano, M. Treatment of Alzheimer's disease. N. Engl. J. Med., 1999, 341, 1670-9.
64. Kidd, P.M. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Altern. Med. Rev., 2005, 10, 268-93.
65. Hooshmand, S., Balakrishnan, A, Clark, R.M., Owen, K.Q., Koo, S.I., Arjmandi, B.H. Dietary l-carnitine supplementation improves bone mineral density by suppressing bone turnover in aged ovariectomized rats. Phytomedicine, 2008, 15, 595-601.
66. Colucci, S.; Mori, G.; Vaira, S.; Brunetti, G.; Greco, G.; Mancini, L.; Simone, G.M.; Sardelli, F.; Koverech, A.; Zallone, A.; Grano, M. L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif. Tissue Int., 2005, 6, 458-65.
67. Giorgio C.. Male idiopathic oligoasthenoteratozoospermia. Asian J. Androl., 2006, 8, 143-157
68. Agarwal A, Said T.M.. Carnitines and male infertility. Reprod. Biomed. Online, 2004, 4, 376-84.